Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTH | P32929 | 11/20 | 1.00 |
| ▸ | TOP2A | P11388 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982233 | 1.00 | CTH (1.00) | CTHTOP2AMEN1ALDH1A1LMNA | |
| SCHEMBL31690655 | 0.82 | TOP2A (0.82) | CTHTOP2AMEN1ALDH1A1LMNA | |
| SCHEMBL13611503 | 0.80 | TOP2A (1.00) | CTHTOP2AMEN1ALDH1A1LMNA | |
| SCHEMBL293101 | 0.80 | TOP2A (0.68) | CTHTOP2AMEN1LMNAKMT2A | |
| SCHEMBL2562207 | 0.80 | TOP2A (0.68) | CTHTOP2AMEN1ALDH1A1LMNA | |
| SCHEMBL534248 | 0.80 | TOP2A (0.68) | CTHTOP2AMEN1LMNAKMT2A | |
| SCHEMBL2562208 | 0.80 | TOP2A (0.68) | CTHTOP2AMEN1ALDH1A1LMNA | |
| SCHEMBL31690665 | 0.77 | TOP2A (0.73) | CTHTOP2AMEN1ALDH1A1LMNA | |
| SCHEMBL3059864 | 0.77 | NPC1 (0.68) | CTHTOP2AMEN1ALDH1A1LMNA | |
| SCHEMBL5180987 | 0.77 | TOP2A (1.00) | CTHTOP2AMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309798-A1 | Tumour Treatment Agents and Method | VIVOLUX AB | 2012-12-06 | — | — | US | disclosed |
| EP-2512473-A1 | TUMOUR TREATMENT AGENTS AND METHOD | Vivolux Ab (SE) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011075032-A1 | TUMOUR TREATMENT AGENTS AND METHOD | VIVOLUX AB (SE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309798-A1 | Tumour Treatment Agents and Method | PMS2, PDCD1, TK2 | CTH 876/4885TOP2A 5/4885MEN1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.